Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $1.7 million.

  • Beam Therapeutics' Cash from Financing Activities rose 3272.58% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.6 million, marking a year-over-year increase of 116195.76%. This contributed to the annual value of $7.7 million for FY2024, which is 9720.16% down from last year.
  • Beam Therapeutics' Cash from Financing Activities amounted to $1.7 million in Q3 2025, which was up 3272.58% from $1.1 million recorded in Q2 2025.
  • Beam Therapeutics' Cash from Financing Activities' 5-year high stood at $473.4 million during Q1 2025, with a 5-year trough of $133000.0 in Q2 2024.
  • In the last 5 years, Beam Therapeutics' Cash from Financing Activities had a median value of $32.0 million in 2022 and averaged $85.7 million.
  • As far as peak fluctuations go, Beam Therapeutics' Cash from Financing Activities soared by 34126808.51% in 2021, and later crashed by 9987.63% in 2024.
  • Beam Therapeutics' Cash from Financing Activities (Quarter) stood at $21.5 million in 2021, then skyrocketed by 48.6% to $32.0 million in 2022, then rose by 5.31% to $33.7 million in 2023, then crashed by 89.78% to $3.4 million in 2024, then crashed by 51.36% to $1.7 million in 2025.
  • Its Cash from Financing Activities stands at $1.7 million for Q3 2025, versus $1.1 million for Q2 2025 and $473.4 million for Q1 2025.